Kittens need two doses of feline leukemia (FeLV) vaccine given three to four weeks apart, starting as early as 8 weeks old. After that initial series, adult cats get a booster one year later, then every one to three years depending on their risk of exposure. Many low-risk indoor cats stop receiving the vaccine entirely after kittenhood.
The Kitten Series
All kittens are generally recommended to receive the FeLV vaccine regardless of lifestyle, since their future living situation and exposure risk can be hard to predict. The initial series consists of two doses administered about 21 days apart, typically starting between 8 and 12 weeks of age. This two-dose series is essential because a single shot doesn’t produce reliable immunity on its own.
Before that first dose, your kitten should be tested for feline leukemia. A simple blood test confirms whether the cat is already infected. Vaccinating a cat that’s already positive provides no benefit and carries the risk of unnecessary side effects. The American Association of Feline Practitioners recommends testing before initial vaccination as standard practice.
Booster Schedule for Adult Cats
After completing the kitten series, cats receive a single booster one year later. From that point forward, the schedule depends on how likely your cat is to encounter the virus. Cats that go outdoors, live with FeLV-positive cats, or have contact with cats of unknown status are considered at continuing risk and typically receive boosters every year or every two years.
Research on recombinant FeLV vaccines shows that immunity can last well beyond a single year. In one study tracking 30 cats over more than three years, vaccinated cats remained protected against repeated feline leukemia exposure for the entire observation period, even as their antibody levels gradually declined. This is why some veterinarians extend the interval to every two or three years for cats with moderate risk.
For strictly indoor cats with no exposure to other cats, many veterinarians discontinue the FeLV vaccine after the one-year booster. The reasoning is straightforward: feline leukemia spreads through close contact, shared food bowls, mutual grooming, and bite wounds. A cat that never encounters an infected cat has virtually no chance of contracting the virus, so the benefit of ongoing vaccination drops to near zero.
Why Risk Level Matters So Much
Unlike core vaccines such as rabies and feline distemper, the FeLV vaccine is classified as non-core for adult cats. That means it’s recommended based on individual circumstances rather than for every cat across the board. The key factors that keep a cat in the “at risk” category include outdoor access (even occasional supervised time), living in a multi-cat household where new cats are introduced, and any chance of encountering stray or feral cats.
If your indoor cat escapes occasionally, or if you foster other cats, that changes the calculation. Booster vaccinations in adult cats are generally reserved for those with a continuing risk of exposure. Your vet will reassess your cat’s lifestyle at each visit and adjust recommendations accordingly. A cat that transitions from indoor-outdoor to strictly indoor may not need further boosters, while a newly adopted roommate could put a previously low-risk cat back on the schedule.
Types of FeLV Vaccines
Three main types of FeLV vaccines are available: adjuvanted killed-virus vaccines, a recombinant vaccine that uses a harmless carrier virus to deliver feline leukemia proteins, and a subunit vaccine made from purified viral proteins. The recombinant version (sold under the brand Purevax) is nonadjuvanted, meaning it doesn’t contain the chemical additives used in killed vaccines to boost the immune response. Studies comparing these types head-to-head have found that the recombinant vaccine performs comparably to adjuvanted killed vaccines in preventing persistent infection.
The distinction matters because of a rare but serious risk: injection-site sarcomas. These are aggressive tumors that can develop at the location where a vaccine was given. The estimated rate falls between 1 in 1,000 and 1 in 10,000 vaccinated cats. Adjuvanted vaccines have historically been linked to a higher incidence of these tumors, which is one reason the nonadjuvanted recombinant option has gained popularity.
Where the Shot Goes and Why
To minimize the consequences if an injection-site sarcoma does develop, veterinary guidelines specify exactly where each vaccine should be given. The FeLV vaccine is recommended in the lower left rear leg, while rabies goes in the lower right rear leg, and other vaccines go in the right shoulder area. No vaccine should be given between the shoulder blades.
This placement strategy exists because a tumor on a limb can be treated with amputation if necessary, giving the cat a good chance of survival. A tumor between the shoulder blades is far more difficult to remove completely. Vaccines are also given under the skin rather than into muscle, since subcutaneous lumps are easier to detect early. If you notice a lump at any injection site that persists for more than three weeks, continues to grow, or becomes larger than two centimeters, have your vet examine it promptly.
Testing Before and After Vaccination
Testing isn’t just a pre-vaccination formality. If a vaccinated cat later shows signs of illness, knowing its FeLV status helps your vet distinguish between a new infection and vaccine failure. Cats should be retested after any known exposure to an infected cat or a cat with unknown status, and whenever unexplained illness develops.
Vaccination does not interfere with the standard FeLV blood test, so a positive result in a vaccinated cat means actual infection, not a false reading from the vaccine. This is important because some owners assume their vaccinated cat can’t possibly test positive. The vaccine is highly effective but not 100%, and no vaccine eliminates the need for periodic testing in cats with ongoing exposure risk.